It has already provided the world with two highly-effective corona vaccines with limited side effects. However, this is just the beginning for mRNA technology, industry players say.
"I believe that the low-hanging fruit will be within infectious diseases. We have shown that the technology works really well, when it is injected into muscle, and it provides both antibodies and a t-cell response. It is working very well with Covid-19 and we are currently investigating its potential within other infections diseases," says Morten Søgaard, Vice President and Head of Genome Sciences & Technologies, Worldwide R&D at Pfizer.